212 related articles for article (PubMed ID: 10888269)
41. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
[TBL] [Abstract][Full Text] [Related]
42. Multiple roles for CD4+ T cells in anti-tumor immune responses.
Kennedy R; Celis E
Immunol Rev; 2008 Apr; 222():129-44. PubMed ID: 18363998
[TBL] [Abstract][Full Text] [Related]
43. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.
Waldmann TA; Dubois S; Tagaya Y
Immunity; 2001 Feb; 14(2):105-10. PubMed ID: 11239443
[No Abstract] [Full Text] [Related]
44. Immunotherapy as part of combinations for the treatment of cancer.
Mitchell MS
Int Immunopharmacol; 2003 Aug; 3(8):1051-9. PubMed ID: 12860162
[TBL] [Abstract][Full Text] [Related]
45. NKT cells and tumor immunity--a double-edged sword.
Smyth MJ; Godfrey DI
Nat Immunol; 2000 Dec; 1(6):459-60. PubMed ID: 11101862
[No Abstract] [Full Text] [Related]
46. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
47. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
[TBL] [Abstract][Full Text] [Related]
48. Histamine as an adjunct to immunotherapy.
Naredi P
Semin Oncol; 2002 Jun; 29(3 Suppl 7):31-4. PubMed ID: 12068386
[TBL] [Abstract][Full Text] [Related]
49. Activated killer monocytes: preclinical model systems.
Shinomiya H; Shinomiya M; Stevenson GW; Stevenson HC
Immunol Ser; 1989; 48():101-26. PubMed ID: 2488316
[No Abstract] [Full Text] [Related]
50. [Immunotherapy of parenchymal tumors. Recent progress and theoretical considerations].
Marincola F; Smolik L; Annoni F; Holter WD
Minerva Chir; 1988 Jul; 43(13-14):1111-31. PubMed ID: 3054627
[No Abstract] [Full Text] [Related]
51. Histamine and immune modulation.
Rocklin RE; Beer DJ
Adv Intern Med; 1983; 28():225-51. PubMed ID: 6220582
[No Abstract] [Full Text] [Related]
52. Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment.
Agarwala SS; Sabbagh MH
Expert Opin Biol Ther; 2001 Sep; 1(5):869-79. PubMed ID: 11728221
[TBL] [Abstract][Full Text] [Related]
53. The reticuloendothelial system, cancer and cancer immunotherapy.
Amery WK
J Reticuloendothel Soc; 1977 Jun; 21(6):417-21. PubMed ID: 886546
[No Abstract] [Full Text] [Related]
54. [Interleukin 2, killer cells and cancer].
Timonen T
Duodecim; 1988; 104(9):685-9. PubMed ID: 3049038
[No Abstract] [Full Text] [Related]
55. Histamine dihydrochloride: in the management of acute myeloid leukaemia.
Yang LP; Perry CM
Drugs; 2011 Jan; 71(1):109-22. PubMed ID: 21175244
[TBL] [Abstract][Full Text] [Related]
56. Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia.
Stadtmauer EA
Semin Oncol; 2002 Jun; 29(3 Suppl 7):47-51. PubMed ID: 12068389
[TBL] [Abstract][Full Text] [Related]
57. Preclinical approaches to the development of effective immunotherapeutic protocols for the treatment of metastasis.
Talmadge JE
Prog Clin Biol Res; 1986; 212():197-215. PubMed ID: 3520577
[No Abstract] [Full Text] [Related]
58. Histamine protects T cells and natural killer cells against oxidative stress.
Hansson M; Hermodsson S; Brune M; Mellqvist UH; Naredi P; Betten A; Gehlsen KR; Hellstrand K
J Interferon Cytokine Res; 1999 Oct; 19(10):1135-44. PubMed ID: 10547153
[TBL] [Abstract][Full Text] [Related]
59. The future role of interleukin-2 in cancer therapy.
Lotze MT
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S58-60. PubMed ID: 10685661
[No Abstract] [Full Text] [Related]
60. [Biological effects of interleukin-2 and prospects for its use in the immunotherapy of malignant neoplasms].
Berezhnaia NM; Goretskiĭ BA
Eksp Onkol; 1989; 11(6):38-44. PubMed ID: 2684609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
